How to buy Enanta Pharmaceuticals stock | $48.66

Enanta Pharmaceuticals, Inc is a biotechnology business based in the US. Enanta Pharmaceuticals shares (ENTA) are listed on the NASDAQ and all prices are listed in US Dollars. Enanta Pharmaceuticals employs 141 staff and has a trailing 12-month revenue of around 0.00.

Enanta Pharmaceuticals stock price (NASDAQ: ENTA)

Use our graph to track the performance of ENTA stocks over time.

Enanta Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-07-30.

Latest market close	$48.66
52-week range	$40.32 - $56.97
50-day moving average	$44.31
200-day moving average	$48.66
Wall St. target price	$68.14
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$0.12

Buy Enanta Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Enanta Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Enanta Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Enanta Pharmaceuticals price performance over time

Historical closes compared with the close of $48.66 from 2021-05-28

1 week (2021-07-23)	N/A
1 month (2021-07-02)	10.09%
3 months (2021-05-03)	-8.38%
6 months (2021-01-30)	N/A

1 year (2020-07-30)	N/A
2 years (2019-07-30)	N/A
3 years (2018-07-30)	N/A
5 years (2016-07-30)	N/A

Is Enanta Pharmaceuticals under- or over-valued?

Valuing Enanta Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Enanta Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Enanta Pharmaceuticals's EBITDA

Enanta Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $14.8 million.

The EBITDA is a measure of a Enanta Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Enanta Pharmaceuticals financials

Revenue TTM	$94.2 million
Gross profit TTM	$122.5 million
Return on assets TTM	-10.78%
Return on equity TTM	-16.05%
Profit margin	-78.57%
Book value	$21.60
Market capitalisation	$862.7 million

TTM: trailing 12 months

Shorting Enanta Pharmaceuticals shares

There are currently 1.9 million Enanta Pharmaceuticals shares held short by investors – that's known as Enanta Pharmaceuticals's "short interest". This figure is 7.4% up from 1.7 million last month.

There are a few different ways that this level of interest in shorting Enanta Pharmaceuticals shares can be evaluated.

Enanta Pharmaceuticals's "short interest ratio" (SIR)

Enanta Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Enanta Pharmaceuticals shares currently shorted divided by the average quantity of Enanta Pharmaceuticals shares traded daily (recently around 177319.82922201). Enanta Pharmaceuticals's SIR currently stands at 10.54. In other words for every 100,000 Enanta Pharmaceuticals shares traded daily on the market, roughly 10540 shares are currently held short.

However Enanta Pharmaceuticals's short interest can also be evaluated against the total number of Enanta Pharmaceuticals shares, or, against the total number of tradable Enanta Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Enanta Pharmaceuticals's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Enanta Pharmaceuticals shares in existence, roughly 90 shares are currently held short) or 0.13% of the tradable shares (for every 100,000 tradable Enanta Pharmaceuticals shares, roughly 130 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Enanta Pharmaceuticals.

Find out more about how you can short Enanta Pharmaceuticals stock.

Enanta Pharmaceuticals share dividends

We're not expecting Enanta Pharmaceuticals to pay a dividend over the next 12 months.

Enanta Pharmaceuticals share price volatility

Over the last 12 months, Enanta Pharmaceuticals's shares have ranged in value from as little as $40.32 up to $56.97. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Enanta Pharmaceuticals's is 0.3836. This would suggest that Enanta Pharmaceuticals's shares are less volatile than average (for this exchange).

Enanta Pharmaceuticals overview

Enanta Pharmaceuticals, Inc. , a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

Frequently asked questions

What percentage of Enanta Pharmaceuticals is owned by insiders or institutions?
Currently 11.457% of Enanta Pharmaceuticals shares are held by insiders and 96.98% by institutions. How many people work for Enanta Pharmaceuticals?
Latest data suggests 141 work at Enanta Pharmaceuticals. When does the fiscal year end for Enanta Pharmaceuticals?
Enanta Pharmaceuticals's fiscal year ends in September. Where is Enanta Pharmaceuticals based?
Enanta Pharmaceuticals's address is: 500 Arsenal Street, Watertown, MA, United States, 02472 What is Enanta Pharmaceuticals's ISIN number?
Enanta Pharmaceuticals's international securities identification number is: US29251M1062 What is Enanta Pharmaceuticals's CUSIP number?
Enanta Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 29251M106